- |||||||||| Ilaris (canakinumab) / Novartis
Review, Journal: Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. (Pubmed Central) - Nov 20, 2024
We first review the NLRP3 inflammasome pathway and inflammatory signalling in cardiomyocytes, (myo)fibroblasts and immune cells, such as neutrophils, macrophages and monocytes. Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF.
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Journal: Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies. (Pubmed Central) - Nov 20, 2024
Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF. Combining variant annotation, activity-by-contact maps, and molQTL increases performance to identify causal genes, while informing on directionality which can be translated to successful target identification and drug development.
- |||||||||| minocycline / Generic mfg.
Preclinical, Journal: Effects of Minocycline on Early Wound Healing after Implant Placement: An In (Pubmed Central) - Nov 20, 2024
P4
Combining variant annotation, activity-by-contact maps, and molQTL increases performance to identify causal genes, while informing on directionality which can be translated to successful target identification and drug development. Small doses of minocycline (1??g/mL) promoted the proliferation and migration of HGFs and inhibited collagen degradation in
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Clinical analysis of systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms (Pubmed Central) - Nov 20, 2024
Children with sJIA who present with Kawasaki disease-like clinical symptoms have clinical features of Kawasaki disease and sJIA. Children with Kawasaki disease who present at a young age, have a long fever course, are accompanied by joint symptoms, and are IVIG-resistant need to be alert to the possibility of sJIA and receive timely treatment with hormones and biological agents.
- |||||||||| 8MW2311 / Mabwell (Shanghai) Biosci
Trial suspension, Metastases: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 20, 2024
P1/2, N=216, Suspended,
Our findings suggest that the extent of previous endoscopic sinus surgeries may have a role in influencing clinical outcomes in patients with refractory CRSwNP undergoing treatment with dupilumab. Recruiting --> Suspended
- |||||||||| Stelara (ustekinumab) / J&J
Review, Journal: Beh (Pubmed Central) - Nov 19, 2024
Additionally, the review encompasses treatment strategies, highlighting TNF-alpha inhibitors as pivotal biologics and newer agents like IL-1 inhibitors and Ustekinumab that broaden the therapeutic options for BD. Our work provides insights into the evolving landscape of treatments for BD, emphasizing the expanding role of newer agents alongside established therapies like TNF-alpha inhibitors.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis. (Pubmed Central) - Nov 19, 2024
Patients on dupilumab were compared with patients on other systemic medications, e.g., methotrexate, cyclosporine, or Janus kinase inhibitors, and possible risk factors for weight change during treatment with dupilumab were analysed. In the multivariable analysis, controlling for age at start, sex, asthma, and body mass index at start, dupilumab was associated with higher weight gain than other systemic treatments (3.3 kg, p?=?0.005 [95% CI
- |||||||||| PLX5622 / Daiichi Sankyo
Preclinical, Journal: Microglial depletion rescues spatial memory impairment caused by LPS administration in adult mice. (Pubmed Central) - Nov 19, 2024
Inactivating microglia through minocycline administration replicated the protective effect of microglial depletion on LPS-induced memory impairment...These results strengthen the evidence for the involvement of microglial immunoactivation in LPS-induced synaptic and cognitive malfunctions. They also suggest that targeting microglia may be a potential approach to treating neuroinflammation-associated cognitive dysfunction seen in neurodegenerative diseases.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Journal: Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19. (Pubmed Central) - Nov 19, 2024
The association of high levels of IL-6 with severe cases led to the early evaluation of the anti-IL6 inhibitor tocilizumab as a potential treatment, which unfortunately failed to improve survival in many trials...Moreover, higher increase in EV S was observed in patients with lower antibody response, hyperfibrinogenemia, lower respiratory function, higher blood pressure and shorter outcomes. These findings lay the foundation for future studies characterizing the role of EVs in multiorgan assessment and identifying biomarkers in patients with severe COVID-19 and possible long COVID.
- |||||||||| Review, Journal: IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents. (Pubmed Central) - Nov 19, 2024
Eblasakimab, which disrupts IL-13 and IL-4 signaling pathways, is currently in phase II trials following well-tolerated administration in phase I studies. This narrative review aims to outline the current state of knowledge regarding the effectiveness and safety of these four biologic agents targeting IL-13 signaling.
- |||||||||| Journal: Drugs for asthma. (Pubmed Central) - Nov 19, 2024
This narrative review aims to outline the current state of knowledge regarding the effectiveness and safety of these four biologic agents targeting IL-13 signaling. No abstract available
- |||||||||| Bimzelx (bimekizumab-bkzx) / UCB, Humira (adalimumab) / AbbVie
Preclinical, Journal: Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies. (Pubmed Central) - Nov 19, 2024
Topical application of dexamethasone (DEX) or celastrol (CEL), a natural anti-inflammatory compound reduced the secretion of pro-inflammatory cytokines...Subcutaneous application of adalimumab (ADM) or bimekizumab (BMM) showed anti-psoriatic effects via protein induction of the differentiation marker keratin-10...BMM inhibited the psoriatic expression of AMP genes and induced KRT10 and cell-cell contact genes. The present in vitro model provides a 3D environment with in vivo-like cutaneous responses and represents a promising tool for preclinical investigations.
- |||||||||| Winlevi (clascoterone cream 1%) / Cosmo Pharma
Review, Journal: Innovations in Acne. (Pubmed Central) - Nov 19, 2024
Active, not recruiting --> Completed The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726
- |||||||||| Review, Journal: Innovations in Psoriasis. (Pubmed Central) - Nov 19, 2024
This review discusses therapies that were recently Food and Drug Administration (FDA)-approved for treating psoriasis, including the topical agents tapinarof and roflumilast, deucravacitinib, an oral small molecule that selectively inhibits tyrosine kinase 2, and spesolimab, a monoclonal antibody inhibiting interleukin-36 that became the first FDA-approved treatment for generalized pustular psoriasis flares. Other therapies are in the pipeline, such as orismilast, as well as Mind.Px, a tool for predicting biological response, is also highlighted.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Xolair (omalizumab) / Roche, Novartis
Journal: Alta eficacia de dupilumab en urticaria cr (Pubmed Central) - Nov 19, 2024
These findings highlight the potential of caIL-12 to address challenges of antigen escape and tumor heterogeneity that may limit the efficacy of T-cell therapy against solid tumors. No abstract available
- |||||||||| Omvoh (mirikizumab) / Eli Lilly
New trial, Real-world evidence, Real-world: MIRROR: Mirikizumab Real World Protocol (clinicaltrials.gov) - Nov 19, 2024
P=N/A, N=100, Not yet recruiting,
- |||||||||| carfilzomib / Generic mfg., pomalidomide / Generic mfg.
Trial completion date, Trial primary completion date: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 19, 2024
P1/2, N=101, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Ebglyss (lebrikizumab-lbkz) / Eli Lilly
Journal: Not Available (Pubmed Central) - Nov 18, 2024
Our patient, with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, experienced substantial improvement with dual monoclonal antibody therapy, without major complications or side effects. No abstract available
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Journal, Biopsy: A CASE OF IgG4-RELATED DISEASE WITH CONFIRMED RESPONSE TO DUPILUMAB BY SMALL SALIVARY GLAND BIOPSY (Pubmed Central) - Nov 18, 2024
In addition, serum IgG4 levels decreased after the initiation of dupilumab treatment, and a decrease in IgG4-positive plasma cells was observed on small salivary gland biopsy. Thus, the treatment of inhaled steroid-resistant bronchial asthma with dupilumab can also improve IgG4-related disease, and we confirmed a decrease in IgG4-positive plasma cells in the small salivary glands.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Xolair (omalizumab) / Roche, Novartis
Review, Journal: Anti-IgE therapy in chronic rhinosinusitis with nasal polyps. (Pubmed Central) - Nov 18, 2024
Additionally, further studies are needed to identify biomarkers to predict treatment response and to compare omalizumab with other biologics such as dupilumab, in head-to-head trials. Omalizumab is one of the key T2-targeted therapeutic options for CRSwNP with sustained effectiveness and strong safety profile.
- |||||||||| Simulect (basiliximab) / Novartis
Review, Journal: The Role of Induction Therapy in Lung Transplantation. (Pubmed Central) - Nov 18, 2024
Despite this now common practice, the evidence to support and guide induction immunosuppression following lung transplantation is limited, making the use of induction somewhat controversial. Here, we review the available literature addressing the use of induction immunosuppression in lung transplant recipients.
- |||||||||| Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, Keytruda (pembrolizumab) / Merck (MSD), Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness: Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu (Pubmed Central) - Nov 18, 2024
In the rapidly evolving landscape of urothelial cancer, some of these treatment strategies might be cost effective and improve patients' quality of life. The findings of our review highlight the need for novel, more effective therapeutic strategies.
- |||||||||| Nucala (mepolizumab) / GSK
Journal, Real-world evidence, Real-world: Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States. (Pubmed Central) - Nov 18, 2024
The findings of our review highlight the need for novel, more effective therapeutic strategies. Mepolizumab was associated with significant steroid-sparing benefits and significantly reduced rates of EGPA-related hospitalizations, EGPA relapses, and asthma exacerbations in this real-world study of US patients with EGPA, confirming the benefits of mepolizumab treatment seen in clinical trials.
- |||||||||| sertraline / Generic mfg., minocycline / Generic mfg.
Journal: The molecular mechanisms of steroid hormone effects on cognitive function. (Pubmed Central) - Nov 18, 2024
Steroid hormones are promising compounds for improving cognitive function. Further research is needed to validate these findings through focused investigations into apoptosis, regulation of neuronal cell death, miRNA sponges, interactions with gut microbiota, and the potential efficacy of pharmaceutical agents.
- |||||||||| Winlevi (clascoterone cream 1%) / Cosmo Pharma
Review, Journal: An update on the pharmacological management of acne vulgaris: the state of the art. (Pubmed Central) - Nov 18, 2024
There is a need for a blockbuster acne drug that simultaneously targets the 4 main pathogenic factors involved in the appearance of acne lesions while presenting with minimal side effects. Until such a drug exists, combination therapy will remain the standard of treatment for most acne patients.
|
